Literature DB >> 31179077

Role of wedge resection in bronchial carcinoid (BC) tumors: SEER database analysis.

Mohamed Rahouma1,2, Mohamed Kamel1,2, Navneet Narula3, Abu Nasar1, Sebron Harrison1, Benjamin Lee1, Brendon M Stiles1, Christopher Lau1, Nasser K Altorki1, Jeffrey L Port1.   

Abstract

BACKGROUND: There is a paucity of data regarding the role of wedge resection (WR) in the management of bronchial carcinoid (BC) tumors. In this study, we queried the Surveillance, Epidemiology, and End Results (SEER) database to compare the oncologic outcomes of patients with BC tumors treated with WR or anatomic resection.
METHODS: The SEER database was retrospectively reviewed for patients with BC treated with surgical resection between 1973-2013. Patients who underwent WR were compared to those who underwent lobectomy or segmentectomy (Lob/Seg). Patients with multiple primaries and those who underwent pneumonectomy or have an unspecified surgical procedure were excluded. Differences in demographics and clinicopathological data were compared using Chi (χ2) test or Mann Whitney U test. Overall and cancer specific survival (OS, CSS) were estimated using Kaplan-Meier method and differences were compared using log-rank test. Cox-regression multivariable analysis (MVA) was performed to explore factors associated with worse CSS. Propensity-score matching analysis was done to compare survival differences between WR and Lob/Seg.
RESULTS: A total of 22,350 patients with BC were identified, of them 4,450 met our inclusion criteria (3,511 Lob/Seg, vs. 939 WR). The median age was 59.0 years [interquartile range (IQR) =49.0-68.0], 67.6% were females and the median tumor size was 2 cm (1.5-3 cm). 4,119 patients had typical carcinoid (TC) and 331 had atypical carcinoid (AC). WR was performed more frequently in elderly patients, females, lower lobe tumors, TC's and in earlier stage disease. For patients with TC, there was no difference in CSS between WR and Lob/Seg in both the entire cohort (P=0.654) and in the propensity matched groups (P=0.900). However, for patients with AC, Lob/Seg was associated with better CSS compared to WR both in the entire cohort (P<0.001) and in the propensity matched groups (P=0.001). On MVA of the entire cohort, elderly patients, males, blacks, AC and advanced stages had worse CSS. While, the type of the procedure (WR vs. Lob/Seg) was not associated with CSS (HR =1.16, 95% CI: 0.85-1.60).
CONCLUSIONS: A WR may offer equivalent CSS in well-selected patients with early-stage TC. An anatomic resection appears warranted in AC.

Entities:  

Keywords:  SEER database; Wedge resection (WR); bronchial carcinoid tumors; cancer specific survival (CSS)

Year:  2019        PMID: 31179077      PMCID: PMC6531713          DOI: 10.21037/jtd.2019.03.89

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

Review 1.  Clinical presentation and evaluation of neuroendocrine tumors of the lung.

Authors:  Frank C Detterbeck
Journal:  Thorac Surg Clin       Date:  2014-08       Impact factor: 1.750

2.  Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.

Authors:  Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Francis C Nichols; Shauna L Hillman; Dwight E Heron; Bryan F Meyers; Thomas A DiPetrillo; David R Jones; Sandra L Starnes; Angelina D Tan; Benedict D T Daly; Joe B Putnam
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

3.  The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors.

Authors:  Eric Lim; Yoong K Yap; Bianca L De Stavola; Andrew G Nicholson; Peter Goldstraw
Journal:  J Thorac Cardiovasc Surg       Date:  2005-10       Impact factor: 5.209

4.  Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases.

Authors:  G Stamatis; L Freitag; D Greschuchna
Journal:  Eur J Cardiothorac Surg       Date:  1990       Impact factor: 4.191

5.  Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement.

Authors:  C F Thomas; H D Tazelaar; J R Jett
Journal:  Chest       Date:  2001-04       Impact factor: 9.410

Review 6.  Update in pulmonary carcinoid tumors: a review article.

Authors:  R Hage; A Brutel de la Rivière; C A Seldenrijk; J M M van den Bosch
Journal:  Ann Surg Oncol       Date:  2003-07       Impact factor: 5.344

7.  Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification.

Authors:  Maurizio Mezzetti; Federico Raveglia; Tiziana Panigalli; Luigi Giuliani; Fabio Lo Giudice; Stefano Meda; Serena Conforti
Journal:  Ann Thorac Surg       Date:  2003-12       Impact factor: 4.330

8.  Typical and atypical carcinoid tumours: 20-year experience with 89 patients.

Authors:  F Davini; A Gonfiotti; C Comin; A Caldarella; F Mannini; A Janni
Journal:  J Cardiovasc Surg (Torino)       Date:  2008-10-24       Impact factor: 1.888

Review 9.  Is sublobar resection equivalent to lobectomy for surgical management of peripheral carcinoid?

Authors:  Jonathan Afoke; Carol Tan; Ian Hunt; Mustafa Zakkar
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-03-06

10.  Long term survival with thoracoscopic versus open lobectomy: propensity matched comparative analysis using SEER-Medicare database.

Authors:  Subroto Paul; Abby J Isaacs; Tom Treasure; Nasser K Altorki; Art Sedrakyan
Journal:  BMJ       Date:  2014-10-02
View more
  2 in total

Review 1.  Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues.

Authors:  Debora Brascia; Giuseppe Marulli
Journal:  Curr Treat Options Oncol       Date:  2022-10-21

2.  Thoracoscopic segmentectomy with simple routine bronchoscopic inflation for intersegmental plane identification: short and mid-term outcomes compared with lobectomy.

Authors:  Olli Helminen; Johanna Valo; Heidi Andersen; Anna Lautamäki; Jari Räsänen; Eero Sihvo
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.